Chargement en cours...

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane

RATIONALE: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). PATIENT CONCERNS: We...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Medicine (Baltimore)
Auteurs principaux: Krasniqi, Eriseld, Barchiesi, Giacomo, Mazzotta, Marco, Pizzuti, Laura, Villa, Alice, Barba, Maddalena, Vici, Patrizia
Format: Artigo
Langue:Inglês
Publié: Wolters Kluwer Health 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7402792/
https://ncbi.nlm.nih.gov/pubmed/32756099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000021211
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!